The candidate HCV E1E2 vaccine is safe in chronic hepatitis C patients and accellerates the second phase viral decline upon primary response to Peg-Interferon-2A/Ribavirin therapy.

Colombatto P.;Brunetto M.R.;Maina A.M.;Romagnoli V.;Craxì A.;Almasio P.;Madonia S.;Rumi M.G.;Colombo M.;Fargion S.;Ascione A.;Pinzello G.;MONDELLI, MARIO UMBERTO;Muzzi A.;Bianchi F.;Barnaba V.;Sarracino R.;Rappuoli R.;Rosa D.;Montigiani S.;Abrignani S.;Houghton M.;Bonino F.

2009-01-01